These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12050532)

  • 1. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Ansari MS
    J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 3. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
    Medvedev VL
    Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnosis of prostate cancer].
    Strittmatter F
    MMW Fortschr Med; 2010 May; 152(19):40-2. PubMed ID: 20557001
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 6. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSA screening: the bottom line.
    Elhilali MM
    CMAJ; 2000 Mar; 162(6):791-2. PubMed ID: 10750466
    [No Abstract]   [Full Text] [Related]  

  • 8. Repeat prostate biopsy--when, where, and how.
    Presti JC
    Urol Oncol; 2009; 27(3):312-4. PubMed ID: 19414120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical problems of systematic prostate needle biopsy in the detection of prostate cancer].
    Suzuki H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):16-20. PubMed ID: 12557699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 13. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].
    Kimura G; Kimata R; Saito Y; Yoshida K; Nishimura T
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():479-85. PubMed ID: 12599623
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
    Lawrentschuk N; Fleshner N
    BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Eur Urol; 2004 Nov; 46(5):571-8. PubMed ID: 15474265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H; Egawa S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.